Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Mounjaro's appetite-suppressing effect within the first one to two weeks of starting treatment, though visible weight change typically takes a little longer to show. The timeline isn't the same for everyone — dose, starting weight, diet and individual biology all play a role. Mounjaro (tirzepatide) is a prescription-only medicine; a prescriber assesses whether it's clinically suitable for you before any treatment begins. What follows is a plain account of what the evidence and clinical experience actually suggest, week by week.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen you use contains the 2.5 mg dose. Its job is adjustment, not transformation. Tirzepatide activates both GIP and GLP-1 receptors in a way that slows gastric emptying and reduces appetite signals, but at 2.5 mg the effect is deliberately modest, the starter dose is calibrated to minimise nausea and give your digestive system time to settle. Some people feel noticeably less hungry within days. Others notice very little. Both are normal.
What you're unlikely to see yet is a significant change on the scales. A small early drop is common (partly reduced food volume, partly water), but this phase is more about tolerability than results. The most common experiences in this window are mild nausea, some bloating, or a subtle sense of feeling full sooner, occasionally all three. These usually ease within a week or two. A useful habit many patients mention: keeping the pen in the fridge door so the weekly injection fits naturally into a Sunday-morning routine rather than becoming something easy to forget.
The NHS patient information for tirzepatide gives a clear account of what to expect and when to speak to a healthcare professional if side effects feel more than mild.
After four weeks at 2.5 mg, your prescriber will typically move you to 5 mg) and this is usually when people start to notice genuine weight change. Appetite suppression becomes more consistent. Meal portions that once felt normal can start to feel like too much. Cravings for high-calorie foods often become easier to ignore.
Weight loss in this phase is real but rarely dramatic week to week. If you're curious about how quickly Mounjaro will work for you, a steady one to two pounds per week is a reasonable ballpark for many people, though slower progress is common and not a sign treatment isn't working. The body's response to a reduced energy intake tends to accelerate as the dose increases toward 7.5 mg and 10 mg. For a fuller picture of typical weight-loss trajectories at different doses, the rate of weight loss on Mounjaro page goes into more detail.
Gastrointestinal side effects (nausea, loose stools, reflux) are most likely to reappear briefly after each dose step, then settle again. Keeping meals smaller and lower in fat during those first few days after a dose change helps most people manage this.
At higher doses (10 mg, 12.5 mg and 15 mg), the appetite effect tends to be strongest and weight loss most consistent. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that adults taking 15 mg tirzepatide lost an average of around 20–21% of their body weight over 72 weeks. That figure comes from thousands of participants followed over more than a year, it reflects what sustained, well-supported treatment can achieve, not what happens in the first few weeks. A closer look at the full working timeline for Mounjaro covers the later phases in more depth.
Progress in this phase is rarely a straight line. Weight can plateau for a few weeks, then drop again. This is a recognised pattern, not failure, and not a reason to stop without speaking to your prescriber. NICE's guidance on tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing should be reviewed. That review is a clinical conversation, not an automatic end to treatment.
No two timelines look identical. Starting BMI matters: people with a higher starting weight often see faster absolute losses early on, while those closer to the eligibility threshold may see smaller numbers but still meaningful health changes. Metabolic health plays a role too, blood glucose regulation, thyroid function, sleep quality and stress all affect how the body responds to a calorie deficit.
Diet and activity aren't just add-ons. Mounjaro is licensed alongside a reduced-calorie diet and increased activity, and the trial results reflect that combination. Keeping protein intake adequate while appetite is suppressed takes conscious effort and matters for preserving muscle alongside fat. For context on what this all costs in practical and financial terms, the Mounjaro cost and value guide is worth a read before starting.
If you're wondering how fast Mounjaro works and how that translates into the speed of effect compared with other GLP-1 medicines, the tirzepatide onset and effect page covers the pharmacology more directly. And if you want to discuss your own starting point with a prescriber, check your eligibility with our clinical team, it's free, and a real prescriber reads every response the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.